Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors
September 25 2018 - 7:30AM
Business Wire
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the
election of Aoife M. Brennan, M.B., B.Ch., to its board of
directors.
“Dr. Brennan has an impressive track record of success in
advancing the development of numerous drug candidates throughout
her career, with experience in the fields of rare disease,
hematology, and neurology, among other key therapeutic areas,” said
Doug Treco, PhD, President and Chief Executive Officer of Ra
Pharma. “We are thrilled to welcome Aoife to our board, and we look
forward to her insights and expertise.”
Currently, Dr. Brennan serves as Interim President and Chief
Executive Officer and Chief Medical Officer of Synlogic, Inc.
(Nasdaq:SYBX), a publicly-traded company in Cambridge, MA
developing innovative products based on the tools and principles of
synthetic biology to genetically re-program beneficial bacteria.
Dr. Brennan joined Synlogic in 2016 from Biogen, where she most
recently served as Vice President and Head of the Rare Disease
Innovation Unit, which included programs ranging from pre-clinical
to commercial. Prior to joining Biogen, she was director of
clinical development at Tolerx, a biotechnology company focusing on
immunotherapy for Type 1 diabetes. Dr. Brennan holds a medical
degree from Trinity College in Dublin, Ireland and has completed
post-graduate training in internal medicine, endocrinology, and
metabolism. Prior to joining the biotechnology industry, she was a
Clinical Research Fellow in the Division of Endocrinology,
Diabetes, and Metabolism at Beth Israel Deaconess Medical Center
and the Joslin Diabetes Center in Boston, and a Scholar in Clinical
Science at Harvard Medical School.
“Ra Pharma is an innovator in the field of complement
inhibition, with promising ongoing clinical programs in paroxysmal
nocturnal hemoglobinuria and generalized myasthenia gravis,” said
Dr. Brennan. “Ra has the potential to transform treatments for a
range of complement-mediated diseases, and I look forward to
working with the team at this critical time in the Company’s
evolution.”
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical
company focusing on the development of next-generation therapeutics
for complement-mediated diseases. The Company discovers and
develops peptides and small molecules to target key components of
the complement cascade. For more information, please
visit: www.rapharma.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
potential safety, efficacy and regulatory and clinical progress of
our product candidates, including without limitation RA101495 SC,
and our potential to transform treatments for a range of
complement-mediated diseases. All such forward-looking statements
are based on management's current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include the risks that Ra Pharma's product
candidates, including RA101495 SC, will not successfully be
developed or commercialized, in the timeframe we expect or at all;
the risk that topline results as of February 7, 2017 from
the Company's global Phase 2 clinical program evaluating RA101495
SC for the treatment of PNH may not be indicative of final study
results; as well as the other factors discussed in the "Risk
Factors" section in Ra Pharma's most recently filed Annual Report
on Form 10-K, as well as other risks detailed in Ra Pharma's
subsequent filings with the Securities and Exchange
Commission. There can be no assurance that the actual results or
developments anticipated by Ra Pharma will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Ra Pharma. All information in this
press release is as of the date of the release, and Ra Pharma
undertakes no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180925005228/en/
Investors:Argot PartnersNatalie Wildenradt,
212-600-1902natalie@argotpartners.comorMedia:Argot PartnersDavid
Rosen, 212-600-1902david.rosen@argotpartners.com
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Apr 2023 to Apr 2024